CompletedPhase 2NCT00021372
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fox Chase Cancer Center
- Principal Investigator
- Mitchell R. Smith, MD, PhDFox Chase Cancer Center
- Intervention
- estramustine phosphate sodium(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1996 – 2006
Study locations (17)
- Hunterdon Regional Cancer Center, Flemington, New Jersey, United States
- Kimball Medical Center, Lakewood, New Jersey, United States
- South Jersey Regional Cancer Center, Millville, New Jersey, United States
- Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States
- Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
- Community Medical Center, Toms River, New Jersey, United States
- St. Francis Medical Center, Trenton, New Jersey, United States
- Bon Secours-Holy Family Health System, Altoona, Pennsylvania, United States
- Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States
- Pinnacle Health Hospitals, Harrisburg, Pennsylvania, United States
- Conemaugh Memorial Hospital, Johnstown, Pennsylvania, United States
- Saint Mary Regional Center, Langhorne, Pennsylvania, United States
- North Penn Hospital, Lansdale, Pennsylvania, United States
- Paoli Memorial Hospital, Paoli, Pennsylvania, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- +2 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00021372 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital